KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 119 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,320,881 | -31.0% | 985,732 | -7.8% | 0.00% | – |
| Q2 2023 | $1,913,679 | -40.4% | 1,069,094 | +29.6% | 0.00% | -100.0% |
| Q1 2023 | $3,208,273 | +26.5% | 824,749 | +10.6% | 0.00% | 0.0% |
| Q4 2022 | $2,535,491 | -38.4% | 745,733 | -1.1% | 0.00% | 0.0% |
| Q3 2022 | $4,116,000 | +18.9% | 753,779 | -1.9% | 0.00% | 0.0% |
| Q2 2022 | $3,463,000 | -38.5% | 768,098 | +0.5% | 0.00% | 0.0% |
| Q1 2022 | $5,633,000 | +13.0% | 764,335 | -1.4% | 0.00% | 0.0% |
| Q4 2021 | $4,986,000 | +11.7% | 775,551 | +1.1% | 0.00% | 0.0% |
| Q3 2021 | $4,464,000 | -44.9% | 767,060 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $8,105,000 | +3.4% | 785,282 | +5.4% | 0.00% | 0.0% |
| Q1 2021 | $7,837,000 | -35.2% | 745,036 | -4.6% | 0.00% | -50.0% |
| Q4 2020 | $12,087,000 | -2.8% | 780,852 | -8.3% | 0.00% | -33.3% |
| Q3 2020 | $12,435,000 | -27.3% | 851,727 | -5.6% | 0.00% | -25.0% |
| Q2 2020 | $17,095,000 | +16.3% | 902,601 | +17.9% | 0.00% | 0.0% |
| Q1 2020 | $14,701,000 | +3.9% | 765,327 | +3.7% | 0.00% | +33.3% |
| Q4 2019 | $14,143,000 | +98.2% | 737,712 | -0.6% | 0.00% | +50.0% |
| Q3 2019 | $7,137,000 | +93.8% | 741,882 | +20.7% | 0.00% | +100.0% |
| Q2 2019 | $3,683,000 | +4.6% | 614,764 | +2.0% | 0.00% | 0.0% |
| Q1 2019 | $3,520,000 | -38.3% | 602,748 | -0.9% | 0.00% | -50.0% |
| Q4 2018 | $5,702,000 | -46.1% | 608,379 | -2.1% | 0.00% | -33.3% |
| Q3 2018 | $10,588,000 | +3.5% | 621,727 | +3.3% | 0.00% | 0.0% |
| Q2 2018 | $10,226,000 | +91.8% | 601,974 | +51.5% | 0.00% | +200.0% |
| Q1 2018 | $5,331,000 | +44.0% | 397,294 | +3.0% | 0.00% | 0.0% |
| Q4 2017 | $3,702,000 | -19.0% | 385,717 | -7.3% | 0.00% | 0.0% |
| Q3 2017 | $4,570,000 | +24.6% | 416,232 | +2.7% | 0.00% | 0.0% |
| Q2 2017 | $3,668,000 | -3.8% | 405,374 | +36.5% | 0.00% | 0.0% |
| Q1 2017 | $3,813,000 | +39.7% | 297,005 | +2.3% | 0.00% | 0.0% |
| Q4 2016 | $2,730,000 | +3.0% | 290,405 | +6.6% | 0.00% | 0.0% |
| Q3 2016 | $2,650,000 | +53.4% | 272,316 | +5.8% | 0.00% | 0.0% |
| Q2 2016 | $1,727,000 | -22.0% | 257,473 | +3.8% | 0.00% | 0.0% |
| Q1 2016 | $2,214,000 | -33.1% | 248,139 | -0.6% | 0.00% | 0.0% |
| Q4 2015 | $3,307,000 | +30.1% | 249,661 | +3.5% | 0.00% | 0.0% |
| Q3 2015 | $2,541,000 | -46.3% | 241,254 | +38.7% | 0.00% | 0.0% |
| Q2 2015 | $4,732,000 | -9.6% | 173,922 | +1.7% | 0.00% | -50.0% |
| Q1 2015 | $5,236,000 | -5.9% | 171,053 | +15.1% | 0.00% | 0.0% |
| Q4 2014 | $5,562,000 | +5.3% | 148,574 | -1.8% | 0.00% | 0.0% |
| Q3 2014 | $5,284,000 | +26.9% | 151,240 | +69.1% | 0.00% | +100.0% |
| Q2 2014 | $4,164,000 | +40.5% | 89,456 | -6.8% | 0.00% | 0.0% |
| Q1 2014 | $2,964,000 | +22.1% | 95,970 | -9.4% | 0.00% | 0.0% |
| Q4 2013 | $2,428,000 | – | 105,960 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |